Skip to main content
Clinical Trials/NCT07620223
NCT07620223RecruitingNot Applicable

Prophylactic Antibiotics in Preventing Surgical Site Infection After Hepatobiliary Surgery in High-Resistant Settings: A Randomized Clinical Trial

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1 site in 1 country378 target enrollmentStarted: May 24, 2026Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
378
Locations
1

Study Overview

Brief Summary

To analyse the efficacy of different preoperative prophylactic antimicrobial regimens for perioperative infection prevention in patients undergoing hepatobiliary surgery in a high antimicrobial resistance setting.

Detailed Description

Given the high incidence of postoperative surgical site infections (SSI) potentially attributable to bacterial antimicrobial resistance, the use of beta-lactam/beta-lactamase inhibitor combinations for prophylaxis may reduce SSI rates following hepatobiliary surgery in the current era of high antimicrobial resistance. To test this hypothesis, we propose a prospective pragmatic trial comparing piperacillin-tazobactam with the standard prophylactic regimen of cefuroxime for perioperative infection prevention in patients undergoing hepatobiliary surgery.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adult patients aged ≥18 years;
  • Deemed eligible for elective hepatobiliary surgery;
  • Demonstrated comprehension of the study nature and expressed willingness to comply with trial procedures;
  • Capable of providing written informed consent.

Exclusion Criteria

  • History of β-lactam allergy or hypersensitivity
  • Uncontrolled preoperative infection;
  • Current or recent (within the preceding month) systemic corticosteroid administration;
  • Severe hepatic or renal impairment;
  • Pregnancy or lactation;
  • Concurrent enrolment in another clinical trial;
  • Any other condition deemed by the investigator to render the patient unsuitable for study participation.

Investigators

Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Chen Dayu

Pharmacist in Charge

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Study Sites (1)

Loading locations...

Similar Trials